Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Tredje AP fonden

Tredje AP fonden lessened its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 50.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,175 shares of the biopharmaceutical company's stock after selling 51,175 shares during the quarter. Tredje AP fonden's holdings in Royalty Pharma were worth $1,305,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. Rakuten Securities Inc. boosted its stake in Royalty Pharma by 160.5% during the fourth quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 1,003 shares during the period. Jupiter Asset Management Ltd. purchased a new position in Royalty Pharma during the fourth quarter worth about $4,950,000. EverSource Wealth Advisors LLC boosted its stake in shares of Royalty Pharma by 24.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 4,112 shares of the biopharmaceutical company's stock valued at $105,000 after purchasing an additional 818 shares during the period. AGF Management Ltd. purchased a new position in shares of Royalty Pharma in the fourth quarter valued at approximately $2,513,000. Finally, Wealthfront Advisers LLC boosted its stake in shares of Royalty Pharma by 1,655.6% in the fourth quarter. Wealthfront Advisers LLC now owns 188,935 shares of the biopharmaceutical company's stock valued at $4,820,000 after purchasing an additional 178,173 shares during the period. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Stock Performance

NASDAQ:RPRX remained flat at $33.41 during mid-day trading on Wednesday. 2,461,104 shares of the company traded hands, compared to its average volume of 2,827,231. The firm's fifty day simple moving average is $31.88 and its 200-day simple moving average is $28.62. The company has a market capitalization of $19.26 billion, a P/E ratio of 23.04, a PEG ratio of 2.31 and a beta of 0.47. Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $34.20. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.

Remove Ads

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Sell-side analysts predict that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were issued a $0.22 dividend. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. The ex-dividend date was Friday, February 21st. This represents a $0.88 annualized dividend and a yield of 2.63%. Royalty Pharma's dividend payout ratio (DPR) is 60.69%.

Analyst Ratings Changes

Separately, TD Cowen raised shares of Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $41.60.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.